Your browser doesn't support javascript.
loading
Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects.
Gardin, Anne; Gray, Cathy; Neelakantham, Srikanth; Huth, Felix; Davidson, Antonia M; Dumitras, Swati; Legangneux, Eric; Shakeri-Nejad, Kasra.
Affiliation
  • Gardin A; Novartis Institutes for BioMedical Research, Basel, Switzerland. anne.gardin@novartis.com.
  • Gray C; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Neelakantham S; Novartis Healthcare Pvt. Ltd., Hyderabad, India.
  • Huth F; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Davidson AM; PPD, Austin, TX, USA.
  • Dumitras S; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Legangneux E; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Shakeri-Nejad K; Novartis Institutes for BioMedical Research, Basel, Switzerland.
Eur J Clin Pharmacol ; 74(12): 1593-1604, 2018 Dec.
Article in En | MEDLINE | ID: mdl-30105453
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rifampin / Azetidines / Benzyl Compounds / Receptors, Lysosphingolipid / Cytochrome P-450 CYP2C9 Type of study: Prognostic_studies Limits: Adolescent / Adult / Female / Humans / Male Language: En Journal: Eur J Clin Pharmacol Year: 2018 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rifampin / Azetidines / Benzyl Compounds / Receptors, Lysosphingolipid / Cytochrome P-450 CYP2C9 Type of study: Prognostic_studies Limits: Adolescent / Adult / Female / Humans / Male Language: En Journal: Eur J Clin Pharmacol Year: 2018 Document type: Article Affiliation country: Country of publication: